Iron, oxidative stress, and clinical outcomes

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

It is well known that iron is pro-oxidant. Chronic kidney disease (CKD) is a pro-oxidant state, and intravenous administration of iron is frequently used to correct anemia. On one hand, there is little doubt that iron causes oxidative stress. On the other, it is far from clear whether oxidative stress, so generated, leads to poor clinical outcomes. Iron has benefits that may be independent of the correction of anemia. Furthermore, concerns surround the use of high doses of erythropoietin in causing excess heart failure and death in patients with CKD. Thus, it would be prudent if iron were to continue to be used judiciously in patients who require erythropoietin. Iron, given orally, would be the preferred first-line agent in patients not on hemodialysis. In patients with sepsis, intravenous treatment with iron should be avoided, because, in animal experiments, intravenous administration of iron can compound the inflammatory response and increase mortality. Clinical trials are needed to ascertain the risk and benefits of the intravenous administration of iron in patients with CKD.

Original languageEnglish
Pages (from-to)1195-1199
Number of pages5
JournalPediatric Nephrology
Volume23
Issue number8
DOIs
StatePublished - Aug 2008

Fingerprint

Oxidative Stress
Iron
Chronic Renal Insufficiency
Intravenous Administration
Erythropoietin
Anemia
Reactive Oxygen Species
Iron Compounds
Proxy
Renal Dialysis
Sepsis
Heart Failure
Clinical Trials
Mortality

Keywords

  • Cardiovascular disease
  • Chronic kidney disease
  • Iron
  • Oxidative stress
  • Proteinuria
  • Randomized trial

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health

Cite this

Iron, oxidative stress, and clinical outcomes. / Agarwal, Rajiv.

In: Pediatric Nephrology, Vol. 23, No. 8, 08.2008, p. 1195-1199.

Research output: Contribution to journalArticle

@article{82d8d0940f1b49e0834f40bba08df8cf,
title = "Iron, oxidative stress, and clinical outcomes",
abstract = "It is well known that iron is pro-oxidant. Chronic kidney disease (CKD) is a pro-oxidant state, and intravenous administration of iron is frequently used to correct anemia. On one hand, there is little doubt that iron causes oxidative stress. On the other, it is far from clear whether oxidative stress, so generated, leads to poor clinical outcomes. Iron has benefits that may be independent of the correction of anemia. Furthermore, concerns surround the use of high doses of erythropoietin in causing excess heart failure and death in patients with CKD. Thus, it would be prudent if iron were to continue to be used judiciously in patients who require erythropoietin. Iron, given orally, would be the preferred first-line agent in patients not on hemodialysis. In patients with sepsis, intravenous treatment with iron should be avoided, because, in animal experiments, intravenous administration of iron can compound the inflammatory response and increase mortality. Clinical trials are needed to ascertain the risk and benefits of the intravenous administration of iron in patients with CKD.",
keywords = "Cardiovascular disease, Chronic kidney disease, Iron, Oxidative stress, Proteinuria, Randomized trial",
author = "Rajiv Agarwal",
year = "2008",
month = "8",
doi = "10.1007/s00467-007-0673-1",
language = "English",
volume = "23",
pages = "1195--1199",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Iron, oxidative stress, and clinical outcomes

AU - Agarwal, Rajiv

PY - 2008/8

Y1 - 2008/8

N2 - It is well known that iron is pro-oxidant. Chronic kidney disease (CKD) is a pro-oxidant state, and intravenous administration of iron is frequently used to correct anemia. On one hand, there is little doubt that iron causes oxidative stress. On the other, it is far from clear whether oxidative stress, so generated, leads to poor clinical outcomes. Iron has benefits that may be independent of the correction of anemia. Furthermore, concerns surround the use of high doses of erythropoietin in causing excess heart failure and death in patients with CKD. Thus, it would be prudent if iron were to continue to be used judiciously in patients who require erythropoietin. Iron, given orally, would be the preferred first-line agent in patients not on hemodialysis. In patients with sepsis, intravenous treatment with iron should be avoided, because, in animal experiments, intravenous administration of iron can compound the inflammatory response and increase mortality. Clinical trials are needed to ascertain the risk and benefits of the intravenous administration of iron in patients with CKD.

AB - It is well known that iron is pro-oxidant. Chronic kidney disease (CKD) is a pro-oxidant state, and intravenous administration of iron is frequently used to correct anemia. On one hand, there is little doubt that iron causes oxidative stress. On the other, it is far from clear whether oxidative stress, so generated, leads to poor clinical outcomes. Iron has benefits that may be independent of the correction of anemia. Furthermore, concerns surround the use of high doses of erythropoietin in causing excess heart failure and death in patients with CKD. Thus, it would be prudent if iron were to continue to be used judiciously in patients who require erythropoietin. Iron, given orally, would be the preferred first-line agent in patients not on hemodialysis. In patients with sepsis, intravenous treatment with iron should be avoided, because, in animal experiments, intravenous administration of iron can compound the inflammatory response and increase mortality. Clinical trials are needed to ascertain the risk and benefits of the intravenous administration of iron in patients with CKD.

KW - Cardiovascular disease

KW - Chronic kidney disease

KW - Iron

KW - Oxidative stress

KW - Proteinuria

KW - Randomized trial

UR - http://www.scopus.com/inward/record.url?scp=46949110940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46949110940&partnerID=8YFLogxK

U2 - 10.1007/s00467-007-0673-1

DO - 10.1007/s00467-007-0673-1

M3 - Article

VL - 23

SP - 1195

EP - 1199

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 8

ER -